Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment

Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment

Lysyl oxidase-like 2 (LOXL2) is an enzyme that promotes scaffolding of extracellular matrix proteins. Here the authors show that LOXL2 is crucial for pressure-overload induced cardiac fibrosis, and that antibody-mediated inhibition or genetic disruption ofLoxl2in mice shows therapeutic potential for...

Full description

Bibliographic Details
Main Authors: Jin Yang, Konstantinos Savvatis, Jong Seok Kang, Peidong Fan, Hongyan Zhong, Karen Schwartz, Vivian Barry, Amanda Mikels-Vigdal, Serge Karpinski, Dmytro Kornyeyev, Joanne Adamkewicz, Xuhui Feng, Qiong Zhou, Ching Shang, Praveen Kumar, Dillon Phan, Mario Kasner, Begoña López, Javier Diez, Keith C. Wright, Roxanne L. Kovacs, Peng-Sheng Chen, Thomas Quertermous, Victoria Smith, Lina Yao, Carsten Tschöpe, Ching-Pin Chang
Format: Article
Language:English
Published: Nature Publishing Group 2016-12-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/ncomms13710

Internet

https://doi.org/10.1038/ncomms13710

Similar Items